NeoGenomics Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de NeoGenomics ont diminué à un taux annuel moyen de -21.7%, tandis que le secteur Healthcare a vu ses bénéfices augmenter de en à 4% par an. Les revenus ont augmenté de en à un taux moyen de 10.2% par an.
Informations clés
-21.68%
Taux de croissance des bénéfices
-21.31%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 8.50% |
| Taux de croissance des recettes | 10.19% |
| Rendement des fonds propres | -11.97% |
| Marge nette | -13.30% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • May 01
NEO: Expanded Test Access And Coverage Will Support Long Term Upside
Analysts have revised their fair value estimate for NeoGenomics from $17.00 to about $23.43. This change reflects updated assumptions for long term revenue growth, profit margins, and a higher future P/E multiple.
Mise à jour du récit • Apr 17
NEO: Medicare Test Coverage Will Support Bullish Repricing Through 2026 Guidance
Analysts have trimmed their price target on NeoGenomics from about $14.81 to roughly $14.19, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that modestly reset expectations while keeping the broader thesis intact. What's in the News PanTracer LBx received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043.
Mise à jour du récit • Apr 03
NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026
Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).Mise à jour du récit • Mar 19
NEO: New Medicare Coverage Will Drive Bullish Repricing Through 2026 Guidance
Analysts have kept their $14.81 price target for NeoGenomics unchanged, citing stable modeled revenue growth, profit margins, and future P/E assumptions as the basis for maintaining their view. What's in the News Medicare, through the MolDX program, granted coverage for NeoGenomics' PanTracer LBx liquid biopsy test for plasma based genomic profiling in solid tumors, expanding access for Medicare patients to a blood based comprehensive genomic profiling assay that evaluates more than 500 genes with a seven day turnaround (Key Developments).Mise à jour du récit • Mar 05
NEO: Legal Victory And 2025–2026 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on NeoGenomics from about $14.43 to roughly $14.81, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News NeoGenomics launched RaDaR ST, a circulating tumor DNA assay for molecular residual disease that uses patient specific, tumor informed panels and whole exome sequencing to track up to 48 tumor variants with an LOD95 of 11 ppm.Mise à jour du récit • Feb 19
NEO: Liquid Biopsy Expansion And Legal Win Will Support Long Term Upside
Analysts have kept their $17.00 price target for NeoGenomics unchanged, reflecting only small model tweaks to the discount rate, revenue growth assumptions, profit margin expectations, and future P/E that do not materially alter their overall view of the stock. What's in the News Issued earnings guidance for 2026 with expected consolidated revenue of US$793 million to US$801 million and a projected net loss of US$63 million to US$50 million.Mise à jour du récit • Feb 05
NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data
Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.Seeking Alpha • Jan 25
NeoGenomics: Distribution Moat In Community Oncology
Summary NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration. NEO trades at a significant discount to sector peers on EV/Sales and P/S, offering a margin of safety if execution on MRD and margin expansion materializes. Read the full article on Seeking AlphaMise à jour du récit • Jan 22
NEO: Legal Win And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target for NeoGenomics to about US$14.43 from roughly US$13.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that refine their view of the company’s long-term earnings power. What's in the News Issued preliminary unaudited guidance for the fourth quarter of 2025 with expected total revenue of about US$190 million and year over year growth of 11%, and full year 2025 revenue of about US$727 million with year over year growth of 10% (company guidance).Mise à jour du récit • Jan 08
NEO: Future Liquid Biopsy Data Pipeline Will Support Stronger Long Term Outlook
Analysts have lifted their fair value estimate for NeoGenomics from US$14.00 to US$17.00. They cite updated assumptions around revenue growth, profit margins and future P/E that they believe better reflect the company’s outlook.Mise à jour du récit • Dec 14
NEO: Upcoming Trial Readouts And Guidance Will Drive Bullish Repricing
Narrative Update on NeoGenomics Analysts have modestly raised their price target on NeoGenomics to approximately 13.44 dollars from about 13.17 dollars, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a nearly unchanged discount rate and profit margin outlook. What's in the News Upcoming SABCS 2025 presentations will showcase RaDaR 1.0 ctDNA data from the SURVIVE HERoes Phase III trial and CLEVER study in early breast cancer, supporting ctDNA guided surveillance and earlier intervention strategies (company announcement).Mise à jour du récit • Nov 29
NEO: Upcoming Research and Earnings Guidance Will Shape Market Expectations
Analysts have slightly raised their price target for NeoGenomics from $13.06 to $13.17 per share. This reflects updated assessments of future profitability and market growth potential.Mise à jour du récit • Nov 15
NEO: Upcoming Research Presentations Are Expected To Drive Solid Tumor Detection Momentum
Analysts have raised their fair value estimate for NeoGenomics from $11.72 to $13.06. This change is attributed to slightly improved revenue growth projections, as well as a modest increase in profit margins and future valuation multiples.Mise à jour du récit • Nov 01
NEO: Upcoming Research Presentations Will Accelerate Future Oncology Diagnostic Opportunities
Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.Mise à jour du récit • Oct 18
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple. What's in the News NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin.Mise à jour du récit • Aug 30
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.Article d’analyse • Aug 27
Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Jul 30
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • May 23
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 25% in the last thirty...
Nouveau récit • Mar 23
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.Article d’analyse • Mar 08
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 28% in the last thirty...Seeking Alpha • Feb 28
NeoGenomics: Decent Fundamentals, But Still Overvalued
Summary NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern. Intrinsic value calculations using the Graham's Formula and DCF model suggest the stock may not yet be done falling. I am recommending caution. Read the full article on Seeking AlphaArticle d’analyse • Feb 18
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Jan 14
What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash
NeoGenomics, Inc. ( NASDAQ:NEO ) shares have had a horrible month, losing 29% after a relatively good period...Article d’analyse • Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders are no doubt pleased to see that the share price has bounced 25% in the...Article d’analyse • Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders would be excited to see that the share price has had a great month...Article d’analyse • Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment NeoGenomics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 746 | -99 | 347 | 36 |
| 31 Dec 25 | 727 | -108 | 346 | 37 |
| 30 Sep 25 | 709 | -113 | 345 | 36 |
| 30 Jun 25 | 689 | -104 | 345 | 35 |
| 31 Mar 25 | 672 | -78 | 336 | 34 |
| 31 Dec 24 | 661 | -79 | 330 | 31 |
| 30 Sep 24 | 644 | -78 | 323 | 30 |
| 30 Jun 24 | 628 | -79 | 321 | 28 |
| 31 Mar 24 | 611 | -84 | 317 | 28 |
| 31 Dec 23 | 592 | -88 | 314 | 27 |
| 30 Sep 23 | 575 | -96 | 315 | 27 |
| 30 Jun 23 | 552 | -115 | 318 | 29 |
| 31 Mar 23 | 530 | -126 | 312 | 30 |
| 31 Dec 22 | 510 | -144 | 311 | 30 |
| 30 Sep 22 | 497 | -163 | 293 | 32 |
| 30 Jun 22 | 489 | -147 | 303 | 32 |
| 31 Mar 22 | 486 | -36 | 291 | 27 |
| 31 Dec 21 | 484 | -8 | 284 | 22 |
| 30 Sep 21 | 485 | 49 | 255 | 15 |
| 30 Jun 21 | 489 | 72 | 211 | 10 |
| 31 Mar 21 | 454 | -11 | 196 | 9 |
| 31 Dec 20 | 444 | 4 | 192 | 8 |
| 30 Sep 20 | 425 | -5 | 187 | 8 |
| 30 Jun 20 | 405 | -5 | 184 | 9 |
| 31 Mar 20 | 419 | 3 | 182 | 9 |
| 31 Dec 19 | 409 | 8 | 175 | 8 |
| 30 Sep 19 | 378 | 2 | 164 | 7 |
| 30 Jun 19 | 343 | 2 | 147 | 5 |
| 31 Mar 19 | 309 | 6 | 134 | 3 |
| 31 Dec 18 | 277 | 6 | 114 | 3 |
| 30 Sep 18 | 262 | 8 | 103 | 3 |
| 30 Jun 18 | 252 | -1 | 100 | 4 |
| 31 Mar 18 | 246 | -9 | 96 | 4 |
| 31 Dec 17 | 240 | -11 | 94 | 4 |
| 30 Sep 17 | 239 | -27 | 98 | 4 |
| 30 Jun 17 | 241 | -26 | 98 | 4 |
| 31 Mar 17 | 242 | -29 | 99 | 4 |
| 31 Dec 16 | 232 | -31 | 88 | 5 |
| 30 Sep 16 | 211 | -18 | 85 | 6 |
| 30 Jun 16 | 175 | -12 | 70 | 5 |
| 31 Mar 16 | 136 | -7 | 55 | 5 |
| 31 Dec 15 | 100 | -3 | 41 | 4 |
| 30 Sep 15 | 98 | 0 | 39 | 3 |
| 30 Jun 15 | 96 | 0 | 39 | 3 |
Des revenus de qualité: NEO n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: NEO n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: NEO n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 21.7% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de NEO au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: NEO n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Healthcare ( 17% ).
Rendement des fonds propres
ROE élevé: NEO a un retour sur capitaux propres négatif ( -11.97% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 22:15 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
NeoGenomics, Inc. est couverte par 25 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |
| Michael Ryskin | BofA Global Research |